Lilly describes it as a triple hormone receptor agonist, sometimes called a "triple G," because retatrutide targets three hormone receptorsGLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors
Gastroparesis-like symptoms associated with Ozempic, Wegovy, Mounjaro and other GLP-1 receptor agonists may resolve after stopping use of the medications
Mechanistic work demonstrated that GLP-1 signalling can also modulate intestinal epithelial integrity, mucosal immune responses and the microbiome in pre-clinical colitis models, providing a biologically plausible rationale for a role beyond weight reduction [2]
The dose may have been to blame
Statements Data availability statement The original contributions presented in the study are included in the article/supplementary material
You might maintain your results